A Phase 1 interventional study of HBM7020 in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 122nd largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 17 of the 20 other live ones, and was the 153rd registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:
The Bionics Institute of Australia · Sites in Australia
Ages 18–75
Candid Therapeutics · Sites in Australia
Ages 18–65 · Healthy volunteers
Kali Therapeutics, Inc. · Sites in Australia, New Zealand
Ages 18–75
Seismic Therapeutic AU Pty Ltd · Sites in Australia
Ages 18–75
Kali Therapeutics, Inc. · Sites in Australia
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 30 · Phase 3 72 · Phase 4 13
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 63 is below the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 469 across the 140 interventional studies, 559 across the 13 observational. Of the 131 that completed or were terminated, 94 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 154 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 18 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 7 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Rheumatoid with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT07234773Kali Therapeutics, Inc.A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). | 2027-02 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT07017686The Bionics Institute of AustraliaThe Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis | 2027-09 |
| NCT07455578Seismic Therapeutic AU Pty LtdStudy of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).
The criteria were revised on the registry on Nov 5, 2026. See what changed
Key Inclusion Criteria for Healthy Participants (Part 1)
Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 2)
Key Disease-Specific Inclusion Criteria for Patient Participants (Part 2)
Active moderate to severe disease consistent with protocol-defined disease activity criteria for:
Key Inclusion Criteria for Rescreening Participants (Part 2)
Key Exclusion Criteria for Parts 1 and 2
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants and participants with seropositive systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), or Sjögren's disease (SjD) will receive HBM7020 in sequential dose-escalation cohorts during Part 1 and Part 2a, respectively.
Drug: HBM7020
Eligible patients may receive optional retreatment of HBM7020 in Part 2b
Drug: HBM7020
Liquid formulation, administered through intravenous infusion
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48
Time frame: Up to Week 48
Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related Infection
Time frame: Up to Week 24
Number of Participants With Dose limiting AE Evaluation During Dose Escalation
Time frame: Up to Day 15
Number of Participants With Clinically Significant Changes in Vital Signs
Time frame: Up to Week 24
Number of Participants With Clinically Significant Changes in Physical Examination Findings
Time frame: Up to Week 24
Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)
Time frame: Up to Week 20
Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)
Time frame: Up to Week 20
Change From Baseline in Serum Ferritin
Time frame: Up to Week 20
Change From Baseline in Serum Immunoglobulin G (IgG)
Time frame: Up to Week 20
Area Under the Concentration-Time Curve From Time Zero to Last Observable Concentration (AUCt) of HBM7020
Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of HBM7020
Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Maximum Observed Plasma Concentration (Cmax) of HBM7020
Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Time to Maximum Observed Plasma Concentration (tmax) of HBM7020
Time frame: Pre dose on Day 1 up to completion of pharmacokinetic assessments (Day 29)
Number of Participants With Anti-Drug Antibodies (ADA) to HBM7020
Time frame: Up to Week 24
Plan to share: Yes — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Started Sep 2026 (actual). Primary completion is estimated for Nov 2028, 25 months after the start.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 25 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Development & Commercialization, Inc. →